Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 14  |  Issue : 4  |  Page : 807-814

A meta-analysis of adoptive immunotherapy in postoperative hepatocellular carcinoma


1 Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
2 Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
3 Department of Gastroenterology, Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

Correspondence Address:
Bimang Fu
Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Road, Kunming 650101, Yunnan
China
Tao Wu
Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Road, Kunming 650101, Yunnan
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.JCRT_858_17

Rights and Permissions

Background: Adoptive immunotherapy (AIT) has been adopted as an adjuvant treatment for hepatocellular carcinoma (HCC) patients after curative therapy. However, the outcomes of AIT remain controversial. Purpose: The purpose of this study is to analyze the safety and efficacy of AIT with the recurrence rate and mortality. Materials and Methods: We identified eight randomized controlled trials (RCTs) that adopted AIT to HCC after curative treatments. A meta-analysis was carried out to assess the recurrence rate and mortality. Results: Eight RCTs with 964 patients were included in the study. The overall analysis showed that AIT treatment can not only decrease the 1-year (risk ratio [RR] =0.59, 95% confidence interval [95% CI] = 0.48–0.72, P < 0.00001), 2-year (RR = 0.69, 95% CI = 0.60–0.79, P < 0.00001), and 3-year (RR = 0.82, 95% CI = 0.74–091, P = 0.0001) recurrence, but also decrease the 1-year (RR = 0.43, 95% CI = 0.30–0.62, P = 0.00001), 2-year (RR = 0.56, 95% CI = 0.46–0.74, P < 0.00001), and 3-year (RR = 0.85, 95% CI = 0.73–0.99, P = 0.03) mortality. The results also indicate that the group of lymphokine-activated killer (LAK) cells showed lower pooled RR values compared to the group of cytokine-induced killer cells among every subgroups. However, the AIT treatment failed to affect the 5-year recurrence rate and mortality (P > 0.05). Conclusions: This review provides available evidences that AIT, especially the treatment of LAK, can be used to decrease the early recurrence and mortality of postoperative HCC but may not the long term.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1150    
    Printed23    
    Emailed0    
    PDF Downloaded35    
    Comments [Add]    

Recommend this journal